The Multidisciplinary Association for Psychedelic Studies (MAPS) has been granted the Innovation Passport for MDMA as an adjunct to therapy for post-traumatic stress disorder (PTSD).
Mydecine Innovations Group recently signed a five-year agreement with Johns Hopkins University School of Medicine that will advance research on novel psychedelic therapy.
Ketamine One Capital and Cognetivity Neurosciences have entered into a partnership to study and develop assessments for depression and post-traumatic stress disorder (PTSD).
For the multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD (MAPPUSX) sponsored by MAPS, Numinus will manage two new clinics in Montreal and Vancouver.
Data from Lobe Sciences has demonstrated that combination therapy of psilocybin and N-Acetylcysteine is more effective than monotherapy for mTBI and PTSD.
Heroic Hearts UK research director Grace Blest-Hopley discusses the organisation’s groundbreaking study that will investigate the use of psilocybin for treating brain trauma in veterans.
Heroic Hearts UK CEO Keith Abraham discusses his journey to setting up the organisation which aims to help veterans living with PTSD.
